Piper Jaffray Companies Begins Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)
Investment analysts at Piper Jaffray Companies initiated coverage on shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) in a report released on Monday, MarketBeat.com reports. The firm set an “overweight” rating and a $35.00 price target on the stock. Piper Jaffray Companies’ price objective indicates a potential upside of 68.35% from the company’s current price.
A number of other research firms have also recently issued reports on DCPH. Instinet assumed coverage on Deciphera Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $57.00 target price for the company. JMP Securities assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $38.00 price target for the company. Finally, J P Morgan Chase & Co assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday. They set an “overweight” rating and a $30.00 price target for the company. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $43.40.
Deciphera Pharmaceuticals (NASDAQ:DCPH) traded up 3.18% during mid-day trading on Monday, reaching $20.79. 282,570 shares of the company’s stock were exchanged. The company’s market cap is $663.72 million. The stock has a 50-day moving average price of $21.29 and a 200 day moving average price of $21.29. Deciphera Pharmaceuticals has a 52-week low of $16.11 and a 52-week high of $24.50.
COPYRIGHT VIOLATION WARNING: “Piper Jaffray Companies Begins Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/23/piper-jaffray-companies-begins-coverage-on-deciphera-pharmaceuticals-inc-dcph.html.
In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was bought at an average cost of $17.00 per share, with a total value of $6,375,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.
Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.